eli lilly - Search News

Eli Lilly shares drop

CNBC on MSN · 21h

Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand

Eli Lilly cut its 2024 revenue guidance, saying demand for its obesity and diabetes drugs had not met its lofty expectations. Eli Lilly expects about $3.5 billion in revenue for its diabetes treatment Mounjaro and $1.

The Wall Street Journal on MSN · 21h

Eli Lilly Cuts Sales Outlook After Sluggish Growth for Incretin Drugs

Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases insulin levels.

Barron's · 50m

Eli Lilly Stumbled But Weight-Loss Drugs Will Continue to Fuel Markets. Here’s Why.

Dow, S&P 500, and Nasdaq futures are rising in premarket trading Wednesday as the stock market braces for the latest CPI inflation report and earnings from several big U.S. banks.

Eli Lilly acquires cancer program from Scorpion Therapeutics

Eli Lilly to buy Scorpion Therapeutics' cancer therapy for up to $2.5 billion

Eli Lilly said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of cancer treatments.

The Wall Street Journal on MSN · 1d

Eli Lilly to Buy Scorpion Therapeutics Drug Program in $2.5 Billion Deal

Eli Lilly agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash.

MT Newswires on MSN · 1d

Eli Lilly to Acquire Scorpion Therapeutics' Breast Cancer Candidate For up to $2.5 Billion

Eli Lilly (LLY) agreed to acquire an experimental treatment for breast cancer and other advanced solid tumors from Scorpion Therapeutics for up to $2.5 billion. The purchase price includes an upfront payment and subsequent amounts that Scorpion's shareholders would receive as certain regulatory and sales milestones are achieved.

Pharmaceutical Technology1h

JP Morgan 2025: Eli Lilly misses 2024 revenue estimate by $400m

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

19h

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...

14hon MSN

Eli Lilly & Co. stock underperforms Tuesday when compared to competitors

Shares of Eli Lilly & Co. LLY slipped 6.59% to $744.91 Tuesday, on what proved to be an all-around great trading session for ...

FiercePharma13h

JPM25: Eli Lilly's preliminary '24 sales figures show a continued easing in breakneck GLP-1 market

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

Insider Monkey1d

Why Eli Lilly (LLY) Stock Is Declining Today

The shares of pharmaceutical giant Eli Lilly (LLY) are falling 5% today after the company preannounced lower-than-expected ...

21h

6LLY : Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5...

Eli Lilly expects 2024 revenue of $45.0 billion, reflecting a 32% increase, with strong contributions from Mounjaro and ...

19h

Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

13hon MSN

Buy the weakness in Eli Lilly, says Mizuho Healthcare Strategist Jared Holz

Neil Young delivers verdict on Bob Dylan biopic A Complete Unknown SEC Sues Elon Musk Over Twitter Purchase. Steelers sign ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results